These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1286 related items for PubMed ID: 11704969

  • 1. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R.
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
    Einarson TR, Addis A, Iskedjian M.
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
    [Abstract] [Full Text] [Related]

  • 3. The pharmacoeconomics of venlafaxine in depression.
    Morrow TJ.
    Am J Manag Care; 2001 Sep; 7(11 Suppl):S386-92. PubMed ID: 11570029
    [Abstract] [Full Text] [Related]

  • 4. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK, Kruzikas DT, McLaughlin TP.
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [Abstract] [Full Text] [Related]

  • 5. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
    Griffiths RI, Sullivan EM, Frank RG, Strauss MJ, Herbert RJ, Clouse J, Goldman HH.
    Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
    [Abstract] [Full Text] [Related]

  • 6. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
    Kongsakon R, Bunchapattanasakda C.
    J Med Assoc Thai; 2008 Jul; 91(7):1117-28. PubMed ID: 18839855
    [Abstract] [Full Text] [Related]

  • 7. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.
    Einarson TR, Arikian SR, Casciano J, Doyle JJ.
    Clin Ther; 1999 Feb; 21(2):296-308. PubMed ID: 10211533
    [Abstract] [Full Text] [Related]

  • 8. A pharmacoeconomic evaluation of major depressive disorder (Italy).
    Casciano J, Arikian S, Tarride JE, Doyle JJ, Casciano R.
    Epidemiol Psichiatr Soc; 1999 Feb; 8(3):220-31. PubMed ID: 10638040
    [Abstract] [Full Text] [Related]

  • 9. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
    Malone DC.
    J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
    van Baardewijk M, Vis PM, Einarson TR.
    Curr Med Res Opin; 2005 Aug; 21(8):1271-9. PubMed ID: 16083537
    [Abstract] [Full Text] [Related]

  • 11. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
    Machado M, Iskedjian M, Ruiz IA, Einarson TR.
    Pharmacoeconomics; 2007 Aug; 25(11):979-90. PubMed ID: 17960955
    [Abstract] [Full Text] [Related]

  • 12. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
    Llorca PM, Fernandez JL.
    Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
    [Abstract] [Full Text] [Related]

  • 13. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
    Trivedi MH, Wan GJ, Mallick R, Chen J, Casciano R, Geissler EC, Panish JM.
    J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
    [Abstract] [Full Text] [Related]

  • 14. One-year costs of second-line therapies for depression.
    Sullivan EM, Griffiths RI, Frank RG, Strauss MJ, Herbert RJ, Clouse J, Goldman HH.
    J Clin Psychiatry; 2000 Apr; 61(4):290-8. PubMed ID: 10830151
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
    Nordström G, Despiegel N, Marteau F, Danchenko N, Maman K.
    J Med Econ; 2010 Apr; 13(3):516-26. PubMed ID: 20698748
    [Abstract] [Full Text] [Related]

  • 16. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.
    Freeman H, Arikian S, Lenox-Smith A.
    Pharmacoeconomics; 2000 Aug; 18(2):143-8. PubMed ID: 11067648
    [Abstract] [Full Text] [Related]

  • 17. [Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review].
    Baca Baldomero E, Rubio-Terrés C.
    Actas Esp Psiquiatr; 2006 Aug; 34(3):193-201. PubMed ID: 16736393
    [Abstract] [Full Text] [Related]

  • 18. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N.
    Pharmacoeconomics; 2008 Aug; 26(11):969-81. PubMed ID: 18850765
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
    Lenox-Smith A, Greenstreet L, Burslem K, Knight C.
    Clin Drug Investig; 2009 Aug; 29(3):173-84. PubMed ID: 19243210
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G, Danchenko N, Despiegel N, Marteau F.
    Value Health; 2012 Aug; 15(2):231-9. PubMed ID: 22433753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.